Aurinia Pharmaceuticals (AUPH) is positioned for profitable growth, driven by Lupkynis and pipeline expansion via the Kezar Life Sciences acquisition. AUPH delivered strong 1Q26 results: 24% revenue growth, 48% net income growth, and robust cash flow, reaffirming FY26 guidance for double-digit revenue gains. Tang Capital Management increased its stake above 10%, signaling confidence in AUPH's valuation and future pipeline or strategic optionality.